The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Open accessAbstract
BACKGROUND: We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer. METHODS: We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase-polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung cancer. Mutational analyses of genomic DNA from the Dicer and Drosha genes were performed in a subgroup of ovarian-cancer specimens. Dicer-dependent functional assays were performed by means of in vitro transfection with small interfering RNA (siRNA) and short hairpin RNA (shRNA). RESULTS: Levels of Dicer and Drosha mRNA correlated with the levels of expression of the corresponding protein and were decreased in 60% and 51% of ovarian-cancer specimens, respectively. Low Dicer expression was significantly associated with advanced tumor stage (P=0.007), and low Drosha expression with suboptimal surgical cytoreduction (P=0.02). Cancer specimens with both high Dicer expression and high Drosha expression were associated with increased median survival (>11 years, vs. 2.66 years for other subgroups; P<0.001). We found three independent predictors of reduced disease-specific survival in multivariate analyses: low Dicer expression (hazard ratio, 2.10; P=0.02), high-grade histologic features (hazard ratio, 2.46; P=0.03), and poor response to chemotherapy (hazard ratio, 3.95; P<0.001). Poor clinical outcomes among patients with low Dicer expression were validated in additional cohorts of patients. Rare missense mutations were found in the Dicer and Drosha genes, but their presence or absence did not correlate with the level of expression. Functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. CONCLUSIONS: Our findings indicate that levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
The nuclear RNase III Drosha initiates microRNA processing
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S., et al. (2003) · Nature · doi:10.1038/nature01957 · Cited by 5,114
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Dicer is essential for mouse development
Bernstein, E., Kim, S. Y., Carmell, M. A., Murchison, E. P., Alcorn, H., Li, M. Z., Mills, A. A., Elledge, S. J., Anderson, K. V., & Hannon, G. J. (2003) · Nature Genetics · doi:10.1038/ng1253 · Cited by 1,627
Gene silencing in mammals by small interfering RNAs
McManus, M. T., & Sharp, P. A. (2002) · Nature Reviews Genetics · doi:10.1038/nrg908 · Cited by 1,399
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
The role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,483
MicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNAs in body fluids—the mix of hormones and biomarkers
Cortez, M. A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A. K., & Calin, G. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.76 · Cited by 1,465
Self-citationmiRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S. M., & Voinea, S. C. (2020) · Cells · doi:10.3390/cells9020276 · Cited by 1,344
Genetic variation in microRNA networks: the implications for cancer research
Ryan, B. M., Robles, A. I., & Harris, C. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2867 · Cited by 1,257
Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Non‐coding RNAs: regulators of disease
Taft, R. J., Pang, K. C., Mercer, T. R., Dinger, M., & Mattick, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2638 · Cited by 1,058
MicroRNAs in Cancer: Small Molecules With a Huge Impact
Iorio, M. V., & Croce, C. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0317 · Cited by 959
Paraneoplastic thrombocytosis in ovarian cancer
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812
Self-citationRNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Self-citationThe Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0893 · Cited by 689
Self-citationA network-biology perspective of microRNA function and dysfunction in cancer
Bracken, C. P., Scott, H. S., & Goodall, G. J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.134 · Cited by 668
A MicroRNA Targeting Dicer for Metastasis Control
Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., Enzo, E., Guzzardo, V., Rondina, M., Spruce, T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.017 · Cited by 667
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
MicroRNA and cancer – A brief overview
Acunzo, M., Romano, G., Wernicke, D., & Croce, C. M. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.013 · Cited by 630
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration
Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B. D., Fowler, B. J., Cho, W. G., Kleinman, M. E., Ponicsan, S. L., Hauswirth, W. W., Chiodo, V. A., et al. (2011) · Nature · doi:10.1038/nature09830 · Cited by 601
RETRACTED AND REPLACED: microRNA involvement in human cancer
Iorio, M. V., & Croce, C. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs140 · Cited by 569
RetractedDICER1: mutations, microRNAs and mechanisms
Foulkes, W. D., Priest, J. R., & Duchaine, T. F. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3802 · Cited by 539
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
Aberrant Regulation and Function of MicroRNAs in Cancer
Adams, B. D., Kasinski, A. L., & Slack, F. J. (2014) · Current Biology · doi:10.1016/j.cub.2014.06.043 · Cited by 471
Recurrent Somatic DICER1 Mutations in Nonepithelial Ovarian Cancers
Heravi-Moussavi, A., Anglesio, M. S., Cheng, S.-W. G., Senz, J., Yang, W., Prentice, L., Fejes, A. P., Chow, C., Tone, A., Kalloger, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1102903 · Cited by 466
Dicer1 functions as a haploinsufficient tumor suppressor
Kumar, M. S., Pester, R. E., Chen, C. Y., Lane, K., Chin, C., Lu, J., Kirsch, D. G., Golub, T. R., & Jacks, T. (2009) · Genes & Development · doi:10.1101/gad.1848209 · Cited by 442
Liposomal siRNA nanocarriers for cancer therapy
Ozpolat, B., Sood, A. K., & Lopez-Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 442
Self-citationCui, T. X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R., Roh, M. H., Vatan, L., Szeliga, W., Mao, Y., Thomas, D. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.025 · Cited by 427
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y.-L., Leung, M. L., El-Naggar, A., Creighton, C. J., Suraokar, M. B., et al. (2010) · Nature · doi:10.1038/nature09459 · Cited by 419
Self-citationTaby, R., & Issa, J.-P. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 407
Regulation of Tumor Angiogenesis by EZH2
Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., Armaiz-Pena, G. N., Hu, W., Stone, R. L., Munkarah, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.016 · Cited by 399
Self-citationHigh-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 398
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer
Lopez-Serra, P., & Esteller, M. (2012) · Oncogene · doi:10.1038/onc.2011.354 · Cited by 360
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 352
A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells
Melo, S. A., Moutinho, C., Ropero, S., Calin, G. A., Rossi, S., Spizzo, R., Fernandez, A. F., Davalos, V., Villanueva, A., Montoya, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.007 · Cited by 346
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types
Hummel, R., Hussey, D. J., & Haier, J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.027 · Cited by 344
Causes and Consequences of MicroRNA Dysregulation
Iorio, M. V., & Croce, C. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318250c001 · Cited by 333
Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer
Catto, J. W. F., Miah, S., Owen, H. C., Bryant, H., Myers, K., Dudziec, E., Larré, S., Milo, M., Rehman, I., Rosario, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0744 · Cited by 329
Smalheiser, N. R., Lugli, G., Rizavi, H. S., Torvik, V. I., Turecki, G., & Dwivedi, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033201 · Cited by 324
miRNA control of tumor cell invasion and metastasis
Baranwal, S., & Alahari, S. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25014 · Cited by 316
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 311
Self-citationFrequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
Self-citationInterplay between microRNAs and the epigenetic machinery: An intricate network
Iorio, M. V., Piovan, C., & Croce, C. M. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.005 · Cited by 306
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis
Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581007 · Cited by 288
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., Carroll, A. R., Spannuth, W. A., Deavers, M. T., Allen, J. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40802 · Cited by 283
Self-citationTargeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Han, H. D., Mangala, L. S., Lee, J. W., Shahzad, M. M. K., Kim, H. S., Shen, D., Nam, E. J., Mora, E. M., Stone, R. L., Lu, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0005 · Cited by 282
Self-citationMolecular mechanisms of Dicer: endonuclease and enzymatic activity
Song, M.-S., & Rossi, J. J. (2017) · Biochemical Journal · doi:10.1042/bcj20160759 · Cited by 281
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Otmani, K., & Lewalle, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708765 · Cited by 279
Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy
Rommasi, F., & Esfandiari, N. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03553-8 · Cited by 269
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Suzuki, H. I., Arase, M., Matsuyama, H., Choi, Y. L., Ueno, T., Mano, H., Sugimoto, K., & Miyazono, K. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.09.012 · Cited by 257
Melo, S., Villanueva, A., Moutinho, C., Davalos, V., Spizzo, R., Ivan, C., Rossi, S., Setien, F., Casanovas, O., Simo-Riudalbas, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014720108 · Cited by 253
miR-210 Targets Iron-Sulfur Cluster Scaffold Homologue in Human Trophoblast Cell Lines
Lee, D.-C., Romero, R., Kim, J.-S., Tarca, A. L., Montenegro, D., Pineles, B. L., Kim, E., Lee, J., Kim, S. Y., Draghici, S., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.04.035 · Cited by 135
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease
Wu, D., Hu, Y., Tong, S., Williams, B. R. G., Smyth, G. K., & Gantier, M. P. (2013) · RNA · doi:10.1261/rna.035055.112 · Cited by 71
Noncoding RNAs in DNA Repair and Genome Integrity
Wan, G., Liu, Y., Han, C., Zhang, X., & Lu, X. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5514 · Cited by 50
Dicer Knockdown Inhibits Endothelial Cell Tumor Growth via MicroRNA 21a-3p Targeting of Nox-4
Gordillo, G. M., Biswas, A., Khanna, S., Pan, X., Sinha, M., Roy, S., & Sen, C. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519264 · Cited by 44
Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers
Fletcher, C. E., Dart, D. A., & Bevan, C. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0208 · Cited by 37
Metadata
- Authors
- Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., Deavers, M. T., Mourad-Zeidan, A., Wang, H., Mueller, P., Lenburg, M. E., Gray, J. W., Mok, S., Birrer, M. J., Lopez-Berestein, G., Coleman, R. L., Bar-Eli, M., & Sood, A. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-18
- Volume
- 359
- Issue
- 25
- Pages
- 2641-2650
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2077330022
- Cited by
- 712
- References
- 40
- FWCI
- 60.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.